Nevertheless, in three smaller clinical studies in patients with HER2-positive breast cancer, PIK3CA mutations and PTEN loss did not impact the efficacy of lapatinib, whether administered alone or in combination with chemotherapy [22]–[24]. This evidence concerns the gene PIK3CA and breast carcinoma.